Polycystic ovary syndrome and gestational diabetes mellitus association to pregnancy outcomes: A national register-based cohort study.
gestational diabetes
neonatal outcomes
polycystic ovary syndrome
preeclampsia
pregnancy complications
preterm birth
stillbirth
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
revised:
19
09
2024
received:
20
03
2024
accepted:
09
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
It is well known that both women with polycystic ovary syndrome (PCOS) and women with gestational diabetes mellitus (GDM) have increased risks of adverse pregnancy outcomes, but little is known whether the combination of these two conditions exacerbates the risks. We explored risk estimates for adverse pregnancy outcomes in women with either PCOS or GDM and the combination of both PCOS and GDM. Nationwide register-based historical cohort study in Sweden including women who gave birth to singleton infants during 1997-2015 (N = 281 806). The risks of adverse pregnancy outcomes were estimated for women exposed for PCOS-only (n = 40 272), GDM-only (n = 2236), both PCOS and GDM (n = 1036) using multivariable logistic regression analyses. Risks were expressed as odds ratios with 95% confidence intervals (CIs) and adjusted for maternal characteristics, including maternal BMI. Women with neither PCOS nor GDM served as control group. Maternal outcomes were gestational hypertension, preeclampsia, postpartum hemorrhage, and obstetric anal sphincter injury. Neonatal outcomes were preterm birth, stillbirth, shoulder dystocia, born small or large for gestational age, macrosomia, low Apgar score, infant birth trauma, cerebral impact of the infant, neonatal hypoglycemia, meconium aspiration syndrome and respiratory distress. Based on non-significant PCOS by GDM interaction analyses, we found no evidence that having PCOS adds any extra risk beyond that of having GDM for maternal and neonatal outcomes. For example, the adjusted odds ratio for preeclampsia in women with PCOS-only were 1.18 (95% CI 1.11-1.26), for GDM-only 1.77 (95% CI 1.45-2.15), and for women with PCOS and GDM 1.86 (95% CI 1.46-2.36). Corresponding adjusted odds ratio for preterm birth in women with PCOS-only were 1.34 (95% CI 1.28-1.41), GDM-only 1.64 (95% CI 1.39-1.93), and for women with PCOS and GDM 2.08 (95% CI 1.67-2.58). Women with PCOS had an increased risk of stillbirth compared with the control group (aOR 1.52, 95% CI 1.29-1.80), whereas no increased risk was noted in women with GDM (aOR 0.58, 95% CI 0.24-1.39). The combination of PCOS and GDM adds no extra risk beyond that of having GDM alone, for a number of maternal and neonatal outcomes. Nevertheless, PCOS is still an unrecognized risk factor in pregnancy, exemplified by the increased risk of stillbirth.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Perinatal Foundation
Informations de copyright
© 2024 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).
Références
Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta‐analysis. Hum Reprod. 2016;31(12):2841‐2855.
International Evidence‐based Guideline for the assessment and management of polycystic ovary syndrome 2023. Available from: https://www.monash.edu/__data/assets/pdf_file/0003/3379521/Evidence‐Based‐Guidelines‐2023.pdf
Bellver J, Rodriguez‐Tabernero L, Robles A, et al. Polycystic ovary syndrome throughout a woman's life. J Assist Reprod Genet. 2018;35:25‐39.
Rotterdam EA‐SPcwg. Revised 2003 consensus on diagnostic criteria and long‐term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41‐47.
Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): long‐term metabolic consequences. Metabolism. 2018;86:33‐43.
Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence‐based guideline for the assessment and Management of Polycystic Ovary Syndrome dagger. J Clin Endocrinol Metab. 2023;108:2447‐2469.
Forslund M, Melin J, Stener‐Victorin E, et al. International evidence‐based guideline on assessment and management of PCOS‐A Nordic perspective. Acta Obstet Gynecol Scand. 2024;103:7‐12.
Persson S, Elenis E, Turkmen S, Kramer MS, Yong EL, Sundstrom‐Poromaa I. Fecundity among women with polycystic ovary syndrome (PCOS)‐a population‐based study. Hum Reprod. 2019;34:2052‐2060.
Forslund M, Landin‐Wilhelmsen K, Schmidt J, Brännström M, Trimpou P, Dahlgren E. Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls. Acta Obstet Gynecol Scand. 2019;98:320‐326.
Persson S, Elenis E, Turkmen S, Kramer MS, Yong EL, Poromaa IS. Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome. Fertil Steril. 2021;116:862‐871.
Sweeting A, Wong J, Murphy HR, Ross GP. A clinical update on gestational diabetes mellitus. Endocr Rev. 2022;43:763‐793.
Saeedi M, Cao Y, Fadl H, Gustafson H, Simmons D. Increasing prevalence of gestational diabetes mellitus when implementing the IADPSG criteria: a systematic review and meta‐analysis. Diabetes Res Clin Pract. 2021;172:108642.
Wang H, Li N, Chivese T, et al. IDF diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by International Association of Diabetes in pregnancy study Group's criteria. Diabetes Res Clin Pract. 2022;183:109050.
Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta‐analysis. BMJ. 2022;377:e067946.
Ludvigsson JF, Otterblad‐Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24:659‐667.
Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11:450.
Källen B, Källen K. The Swedish Medical Birth Register ‐ a Summary of Content and Quality. The Swedish Centre for Epidemiology; 2003.
Wallerstedt SM, Wettermark B, Hoffmann M. The first decade with the Swedish prescribed drug register—A systematic review of the output in the scientific literature. Basic Clin Pharmacol Toxicol. 2016;119:464‐469.
Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125‐136.
Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41.
Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687‐708.
Zawadzky JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, eds. Polycystic Ovary Syndrome. Blackwell Scientific; 1992.
Lindqvist M, Persson M, Lindkvist M, Mogren I. No consensus on gestational diabetes mellitus screening regimes in Sweden: pregnancy outcomes in relation to different screening regimes 2011 to 2012, a cross‐sectional study. BMC Pregnancy Childbirth. 2014;14:185.
Fadl H, Saeedi M, Montgomery S, et al. Changing diagnostic criteria for gestational diabetes in Sweden—A stepped wedge national cluster randomised controlled trial—The CDC4G study protocol. BMC Pregnancy Childbirth. 2019;19:398.
Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr. 1996;85:843‐848.
Chen X, Gissler M, Lavebratt C. Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population‐based cohort study. Hum Reprod. 2022;37:1311‐1323.
Fougner SL, Vanky E, Løvvik TS, Carlsen SM. No impact of gestational diabetes mellitus on pregnancy complications in women with PCOS, regardless of GDM criteria used. PLoS One. 2021;16(7):e0254895.
Valgeirsdottir H, Kunovac Kallak T, Sundstrom Poromaa I, et al. Polycystic ovary syndrome and risk of stillbirth: a nationwide register‐based study. BJOG. 2021;128:2073‐2082.
Ni Z, Mei S, You S, et al. Adverse effects of polycystic ovarian syndrome on pregnancy outcomes in women with frozen‐thawed embryo transfer: propensity score‐matched study. Front Endocrinol. 2022;13:878853.
Løvvik TS, Carlsen SM, Salvesen Ø, et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double‐blind, placebo‐controlled trial. Lancet Diabetes Endocrinol. 2019;7:256‐266.
Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high‐income countries: a systematic review and meta‐analysis. Lancet. 2011;377:1331‐1340.
Lemieux P, Benham JL, Donovan LE, Moledina N, Pylypjuk C, Yamamoto JM. The association between gestational diabetes and stillbirth: a systematic review and meta‐analysis. Diabetologia. 2022;65:37‐54.
Fornes R, Simin J, Nguyen MH, et al. Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population‐based study. Reprod Biol Endocrinol. 2022;20:30.
Bahri Khomami M, Boyle JA, Tay CT, et al. Polycystic ovary syndrome and adverse pregnancy outcomes: current state of knowledge, challenges and potential implications for practice. Clin Endocrinol. 2018;88:761‐769.
Stokkeland LMT, Giskeødegård GF, Ryssdal M, et al. Changes in serum cytokines throughout pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2022;107:39‐52.
Koster MP, de Wilde MA, Veltman‐Verhulst SM, et al. Placental characteristics in women with polycystic ovary syndrome. Hum Reprod. 2015;30:2829‐2837.
Kawakita T, Bowers K, Hazrati S, et al. Increased neonatal respiratory morbidity associated with gestational and Pregestational diabetes: a retrospective study. Am J Perinatol. 2017;34:1160‐1168.
Li Y, Wang W, Zhang D. Maternal diabetes mellitus and risk of neonatal respiratory distress syndrome: a meta‐analysis. Acta Diabetol. 2019;56:729‐740.
Newman C, Dunne FP. Metformin for pregnancy and beyond: the pros and cons. Diabetic Medicine: A Journal of the British Diabetic Association. 2022;39:e14700.